期刊文献+

2018年乳腺癌诊疗十大热点问题的思考 被引量:9

Ten hot issues of breast cancer in diagnosis and therapy in 2018
原文传递
导出
摘要 严谨的随机对照研究及可靠的真实世界研究不断改善着临床实践,最新的专家共识及结合中国实际的指南的颁布促进了医师对乳腺癌诊疗的进一步理解。为了进一步阐明学术观点,也为2018年中国临床肿瘤学会乳腺癌指南的修订提供参考,我们梳理了乳腺癌学术交流中经常讨论的十个热点问题,结合自身的治疗理念阐述相应的观点。 The rigorous randomized clinical trials and qualified real world evidence have improved the domestic standardized diagnosis and therapy. Meanwhile, the recent consensus and guideline integrated with Chinese realities have also promoted the breast cancer therapy. To expound our views and to provide suggestions for the revision of breast cancer guideline of Chinese Society of Clinical Oncology, we select ten hot issues to discuss with our experience.
机构地区 解放军第三
出处 《中华外科杂志》 CAS CSCD 北大核心 2018年第2期95-100,共6页 Chinese Journal of Surgery
关键词 乳腺肿瘤 指南 Breast neoplasms Guidebooks
  • 相关文献

参考文献8

二级参考文献56

  • 1Wolff AC, Hammond MEH,Hicks DG, et al. Recommendationsfor human epidermal growth factor receptor 2 testing in breastcancer: American Society of Clinical Oncology/College ofAmerican Pathologists clinical practice guideline update. ArchPathol Lab Med, 2013,138(2) : 241-256. DOI: 10. 5858/arpa.2013-0953-SA. 被引量:1
  • 2Fabi A, Di Benedetto A, Metro G,et al. HER2 protein and genevariation between primary and metastaticbreast cancer :significance and impact on patient care. Clin Cancer Res, 2011,17(7) : 2055-2064. DOI: 10.1158/1078-0432. CCR-10-1920. 被引量:1
  • 3Robert N,Leylan-Jones B, Asmar L, et al. Randomized phase Idstudy of trastuzumab, paclitaxel, and carboplatin compared withtrastuzumab and paclitaxel in women with HER-2 -overexpressingmetastatic breast cancer[ J]. J Clin Oncol, 2006, 24(18) : 2786-2792. 被引量:1
  • 4Wardley AM, Pivot X,Morales-Vasquez F, et al. Randomizedphase II trial of first-line trastuzumab plus docetaxel andcapecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer [ J ]. J Clin Oncol,2010,28(6): 976-983. DOI: 10.1200/JC0.2008.21.6531. 被引量:1
  • 5Andersson M, Lidbrink E, Bjerre K, et al. Phase HI randomizedstudy comparing docetaxel plus trastuzumab with vinorelbine plustrastuzumab as first-line therapy of metastatic or locally advancedhuman epidermal growth factor receptor 2-positive breast cancer:The HERNATA study [J]. J Clin Oncol, 2011, 29 ( 3 ) : 264-271. DOI: 10.12OO/JCO. 2010. 30. 8213. 被引量:1
  • 6Schaller G, Fuchs I, Gonsch T,et al. Phase U Study ofCapecitabine Plus Trastuzumab in Human Epidermal GrowthFactor Receptor 2 -Overexpressing Metastatic Breast CancerPretreated With Anthracyclines or Taxanes [ J ]. J Clin Oncol,2007, 25(22) : 3246-3250. 被引量:1
  • 7Yardley DA, Burris HA, Hanson S, et al. Weekly gemcitabineand trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer[ J]. Clin Breast Cancer,2009 , 9(3) : 178-183. DOI: 10.3816/CBC.2009. n. 029. 被引量:1
  • 8Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab,and docetaxel in HER2-positive metastatic breast cancer [ J ] . NEngl J Med, 2015,372 ( 8 ) : 724-734. DOI: 10. 1056/NEJMoal413513. 被引量:1
  • 9Kaufman B, Mackey JR,Clemens MR,et al. Trastuzumab plusanastrozole versus anastrozole alone for the treatment ofpostmenopausal women with human epidermal growth factorreceptor 2-positive, hormone receptor-positive metastatic breastcancer : Results from the randomized phase ]H TAnDEM study[J]. J Clin Oncol, 2009, 27(33) : 5529-5537. DOI: 10. 1200/JCO.2008.20.6847. 被引量:1
  • 10Johnston S, Pippen J, Pivot X, et al. Lapatinib combined withletrozole versus letrozole and placebo as first-line therapy forpostmenopausal hormone receptor-positive metastatic breast cancer[J]. J Clin Oncol, 2009, 27(33) : 5538-5546. 10.1200/jc0.2009.23.3734. 被引量:1

共引文献130

同被引文献58

引证文献9

二级引证文献115

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部